Leukemia Research
Volume 28, Issue 12 , Pages 1293-1301 , December 2004

Methylation status of cyclin-dependent kinase inhibitor genes within the transforming growth factor beta pathway in human T-cell lymphoblastic lymphoma/leukemia

  • Stuart A. Scott

      Affiliations

    • Department of Pathology, Saskatoon Cancer Centre, Royal University Hospital, University of Saskatchewan, 103 Hospital Drive, Saskatoon, Saskatchewan, Canada S7N 0W8
    • These authors contributed equally to this study.
    • ,
  • Tomofumi Kimura

      Affiliations

    • Department of Pathology, Saskatoon Cancer Centre, Royal University Hospital, University of Saskatchewan, 103 Hospital Drive, Saskatoon, Saskatchewan, Canada S7N 0W8
    • These authors contributed equally to this study.
    • ,
  • Wei-Feng Dong

      Affiliations

    • Department of Pathology, Saskatoon Cancer Centre, Royal University Hospital, University of Saskatchewan, 103 Hospital Drive, Saskatoon, Saskatchewan, Canada S7N 0W8
    • ,
  • Ryo Ichinohasama

      Affiliations

    • Department of Oral Pathology, School of Dentistry, Tohoku University, 4-1 Seiryo Machi, Aoba-Ku, Sendai 980-8575, Japan
    • ,
  • Susan Bergen

      Affiliations

    • Department of Pathology, Saskatoon Cancer Centre, Royal University Hospital, University of Saskatchewan, 103 Hospital Drive, Saskatoon, Saskatchewan, Canada S7N 0W8
    • ,
  • Annette Kerviche

      Affiliations

    • Department of Pathology, Saskatoon Cancer Centre, Royal University Hospital, University of Saskatchewan, 103 Hospital Drive, Saskatoon, Saskatchewan, Canada S7N 0W8
    • ,
  • David Sheridan

      Affiliations

    • Department of Pathology, Saskatoon Cancer Centre, Royal University Hospital, University of Saskatchewan, 103 Hospital Drive, Saskatoon, Saskatchewan, Canada S7N 0W8
    • ,
  • John F. DeCoteau

      Affiliations

    • Department of Pathology, Saskatoon Cancer Centre, Royal University Hospital, University of Saskatchewan, 103 Hospital Drive, Saskatoon, Saskatchewan, Canada S7N 0W8
    • Corresponding Author InformationCorresponding author. Tel.: +1-306-655-2249; fax: +1-306-655-6791.

Received 15 January 2004 ,Accepted 24 March 2004.

References 

  1. Thomas DA, Kantarjian HM. Lymphoblastic lymphoma. Hematol Oncol Clin North Am. 2001;15:51
  2. Ono Y, Fukuhara N, Yoshie O. Transcriptional activity of TAL1 in T cell acute lymphoblastic leukemia (T-ALL) requires RBTN1 or -2 and induces TALLA1, a highly specific tumor marker of T-ALL. J Biol Chem. 1997;272:4576
  3. Bash RO, Hall S, Timmons CF, Crist WM, Amylon M, Smith RG, et al.  Does activation of the TAL1 gene occur in a majority of patients with T-cell acute lymphoblastic leukemia? A childhood oncology group study. Blood. 1995;86:666
  4. Fisch P, Boehm T, Lavenir I, Larson T, Arno J, Forster A, et al.  T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes. Oncogene. 1992;7:2389
  5. Lichty BD, Ackland-Snow J, Noble L, Kamel-Reid S, Dube ID. Dysregulation of HOX11 by chromosome translocations in T-cell acute lymphoblastic leukemia: a paradigm for homeobox gene involvement in human cancer. Leuk Lymphoma. 1995;16:209
  6. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 2000;1:169
  7. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342:1350
  8. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995;268:1336
  9. Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, et al.  Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res. 1999;59:320
  10. Yamamoto H, Sawai H, Perucho M. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res. 1997;57:4420
  11. Schwartz S, Yamamoto H, Navarro M, Maestro M, Reventos J, Perucho M. Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res. 1999;59:2995
  12. Inoue K, Kohno T, Takakura S, Hayashi Y, Mizoguchi H, Yokota J. Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines. Leuk Res. 2001;25:275
  13. Scott S, Kimura T, Ichinohasama R, Bergen S, Magliocco A, Reimer C, et al.  Microsatellite mutations of transforming growth factor-β receptor type II and caspase-5 occur in human precursor T-cell lymphoblastic lymphomas/leukemias in vivo but are not associated with hMSH2 or hMLH1 promoter methylation. Leuk Res. 2003;27:23
  14. Lowsky R, Magliocco A, Ichinohasama R, Reitmair A, Scott S, Henry M, et al.  MSH2-deficient murine lymphomas harbor insertion/deletion mutations in the transforming growth factor beta receptor type 2 gene and display low not high frequency microsatellite instability. Blood. 2000;95:1767
  15. Osada H, Tatematsu Y, Masuda A, Saito T, Sugiyama M, Yanagisawa K, et al.  Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines. Cancer Res. 2001;61:8331
  16. Rich JN, Zhang M, Datto MB, Bigneri DD, Wang XF. Transforming growth factor-beta-mediated p15INK4B induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. J Biol Chem. 1999;274:35053
  17. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 1994;371:257
  18. Pardali K, Kurisaki A, Moren A, ten Dijke P, Kardassis D, Moustakas A. Role of Smad proteins and transcription factor Sp1 in p21(waf1/Cip1) regulation by transforming growth factor-beta. J Biol Chem. 2000;275:29244
  19. Liu X, Sun Y, Ehrlich M, Lu T, Kloog Y, Weinberg RA, et al.  Disruption of TGF-beta growth inhibition by oncogenic ras is linked to p27Kip1 mislocalization. Oncogene. 2000;19:5926
  20. Tsihlias J, Kapusta L, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med. 1999;50:401
  21. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 1998;12:845
  22. Batova A, Diccianni MB, Yu JC, Nobori T, Link MP, Pullen J, et al.  Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res. 1997;57:832
  23. Omura-Minamisawa M, Diccianni MB, Batova A, Chang RC, Bridgeman LJ, Yu J, et al.  Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2000;6:1219
  24. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 1997;57:837
  25. Nakatsuka S, Liu A, Yao M, Takakuwa T, Tomita Y, Hoshida Y, et al.  Methylation of promoter region in p27 gene plays a role in the development of lymphoid malignancies. Int J Oncol. 2003;22:561
  26. Nakamura M, Sakaki T, Hashimoto H, Nakase H, Ishida E, Shimada K, et al.  Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas. Cancer Res. 2001;61:6335
  27. Kibel AS, Christopher M, Faith DA, Bova GS, Goodfellow PJ, Isaacs WB. Methylation and mutational analysis of p27(kip1) genes in prostate carcinoma. Prostate. 2001;48:248
  28. Go JH. Methylation analysis of cyclin-dependent kinase inhibitor genes in primary gastrointestinal lymphomas. Mod Pathol. 2003;16:752
  29. Roman-Gomez J, Castillejo JA, Jimenez A, Gonzalez MG, Moreno F, Rodriguez Mdel C, et al.  5′ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood. 2002;99:2291
  30. Shen L, Kondo Y, Issa JP, Garcia-Manero G. Lack of p21(CIP1) DNA methylation in acute lymphocytic leukemia. Blood. 2002;100:3432
  31. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821
  32. Warnecke PM, Stirzaker C, Melki JR, Millar DS, Paul CL, Clark SJ. Detection and measurement of PCR bias in quantitative methylation analysis of bisulphite-treated DNA. Nucleic Acids Res. 1997;25:4422
  33. Ying J, Srivastava G, Gao Z, Zhang X, Murray P, Ambinder R, et al.  Promoter hypermethylation of the cyclin-dependent kinase inhibitor (CDKI) gene p21WAF1/CIP1/SDI1 is rare in various lymphomas and carcinomas. Blood. 2004;103:743
  34. Kretzschmar M. Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer. Breast Cancer Res. 2000;2:107
  35. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev. 1996;7:93
  36. Verma M, Srivastava S. Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol. 2002;3:755
  37. Kantarjian HM. Adult Acute Lymphocytic Leukemia. Hematol Oncol Clin North Am. 2000;14:1205
  38. Kawamura M, Ohnishi H, Guo SX, Sheng XM, Minegishi M, Hanada R, et al.  Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia. Leuk Res. 1999;23:115
  39. Morosetti R, Kawamata N, Gombart AF, Miller CW, Hatta Y, Hirama T, et al.  Alterations of the p27KIP1 gene in non-Hodgkin’s lymphomas and adult T-cell leukemia/lymphoma. Blood. 1995;86:1924
  40. Ponce-Castaneda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, et al.  p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res. 1995;55:1211
  41. Worm J, Bartkova J, Kirkin AF, Straten P, Zeuthen J, Bartek J, et al.  Aberrant p27Kip1 promoter methylation in malignant melanoma. Oncogene. 2000;19:5111
  42. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997;3:231
  43. Chen B, He L, Savell VH, Jenkins JJ, Parham DM. Inhibition of the interferon-gamma/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21WAF1 promoter region. Cancer Res. 2000;60:3290
  44. Cameron EE, Baylin SB, Herman JG. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood. 1999;94:2445
  45. Leroy K, Haioun C, Lepage E, Le Metayer N, Berger F, Labouyrie E, et al.  p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol. 2002;13:1108
  46. Yang H, Hoshino K, Canalli A, Sanchez-Gonzalez B, Kantarjian H, Issa JP, Garcia-Manero G, Preclinical Studies of the Combination of the Hypomethylating Agent 5-aza-2-Deoxycytidine (Decitabine) and the Histone Deacetylase Inhibitor (HDI) Valproic Acid (VPA) in Leukemic Cell Systems, Blood 2003;102:Abstract 2295.
  47. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, et al.  Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem. 1997;272:22199
  48. Kostyniuk CL, Dehm SM, Batten D, Bonham K. The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases. Oncogene. 2002;21:6340
  49. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA. 2000;97:10014
  50. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al.  WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817
  51. Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB, et al.  Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol. 2002;22:7982
  52. Wu S, Cetinkaya C, Munoz-Alonso MJ, von der Lehr N, Bahram F, Beuger V, et al.  Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene. 2003;22:351

PII: S0145-2126(04)00124-9

doi: 10.1016/j.leukres.2004.03.019

Leukemia Research
Volume 28, Issue 12 , Pages 1293-1301 , December 2004

Article Tools

* Image Usage & Resolution